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Summary The expression of the c-erbB-2 oncogene has been evaluated using an immunohistochemical
technique with the 21N polyclonal antibody in paraffin embedded tissue from 465 patients treated between the
years 1975-1981 for Stage I and II breast cancer. One hundred and four (22%) patients exhibited positive
staining. This was not associated with any other variables. Expression of the oncogene was associated with
significantly poorer survival which was independent of other tumour variables.
The proto-oncogene c-erbB-2 encodes a protein present at the
cell surface which has considerable homology with the epi-
dermal growth factor receptor EGFR (Coussens et al., 1985).
Although originally identified as an oncogene in chemically
induced neuroblastomas in rats (Pahdy et al., 1982; Barg-
mann et al., 1986), recent interest has focused on its role in
human breast cancer. Studies on cell lines derived from
human mammary carcinomas have demonstrated that c-erbB
-2 can be overexpressed by several mechanisms including
gene amplification (Kraus et al., 1987) and this is present in
up to 30% of human breast cancers (Slamon et al., 1987; van
de Vijver et al., 1987; Varley et al., 1987; Zhou et al., 1987).
The development of both polyclonal and monoclonal anti-
bodies to the oncoprotein has allowed its distribution to be
evaluated in histological sections, and its presence and
clinical significance to be correlated with amplification of its
gene and expression of its mRNA (Venter et al., 1987; van de
Vijver et al., 1987; Slamon et al., 1989; Gusterson et al.,
1988). These studies have confirmed that both gene amplifi-
cation and increased transcription of its mRNA are assoc-
iated with expression of this putative receptor at the cell
surface in patients with breast cancer. One study though has
reported that 20% of patients expressing this receptor failed
to exhibit a corresponding amplification of its gene (Berger et
al., 1988) and has concluded that other mechanisms may also
be of importance in allowing it to be expressed.
In both molecular studies and those based on immuno-
logical detection of the protein expression of the receptor has
been associated with the spread of tumour to the axillary
lymph nodes, to the number of nodes involved (Zhou et al.,
1987; Slamon et al., 1987, 1989), larger tumours (van de
Vijver et al., 1987) and with poor histological grade (Berger
et al., 1988). However, the number of patients assessed in
these studies is variable and some have contained too few
patients to evaluate the statistical significance of the data.
Reports of its clinical significance have been conflicting, with
some investigators noting a poorer prognosis in patients
expressing the protein (Slamon et al., 1989; Wright et al.,
1989a; Lovekin et al., 1989) and others reporting little
difference (Barnes et al., 1988; Zhou et al., 1989; Alli et al.,
1988; Gusterson et al., 1988). In addition, many studies have
had only a short follow-up time. In general those studies in
which little difference has been observed have included fewer
patients than those in which significant differences were
noted. In view of the conflicting results, we have evaluated
the expression of c-erbB-2 oncoprotein in histological
material from a large cohort of patients presenting with
primary breast cancer.
Patients and methods
Patients
Four hundred and sixty-five unselected patients, with oper-
able breast cancer, presenting to general surgery clinics in the
Mersey Region were entered into a prospective follow up
study between the years 1975-1981. The patients were staged
clinically according to the international TNM system. The
presence or absence of metastatic disease was confirmed by
skeletal survey or bone scan and in some cases by urinary
hydroxproline estimations. Only patients with operable
cancer (T,13N0_,Mo) were included in this study.
All patients were treated by either modified radical mastec-
tomy or simple mastectomy with axillary sampling. The diag-
nosis of breast cancer was confirmed histologically as was the
presence or absence of axillary metastases. The clinical stag-
ing was modified after the histological examination. Oestro-
gen receptor status was determined in all patients by a ligand
binding competitive inhibition assay previously described
(Cooke et al., 1979). No patients received any adjuvant
systemic therapy.
Staining
Formaldehyde fixed and paraffin-embedded blocks contain-
ing specimens of the original tumours from 465 patients were
obtained. In addition, blocks were obtained from 100
patients with both benign fibrocystic disease and fibroaden-
omas who had undergone biopsy. Multiple 5 mm micro-
scopic sections were cut, dewaxed in xylene and rehydrated
through graded alcohols before being incubated for 20 min
with 0.6% hydrogen peroxide in methanol to inhibit endo-
genous peroxidases. After washing in phosphate buffered
saline (PBS pH 7.4), they were pre-incubated at room tem-
perature for 20 min with normal swine serum diluted 1/5
PBS/0.5% bovine serum albumin (BSA) (w/v) to reduce any
non-specific binding of the conjugated second antibody. The
excess was washed off and the sections were incubated for
between 60 to 90 min with the 21N primary polyclonal anti-
body raised in rabbits (the gift of Dr W. Gullick) diluted to
6.6ftml1'. A second incubation using horse radish peroxi-
dase conjugated swine anti-rabbit serum (Dako; Bucks, UK)
was carried out at a dilution of 1:50 for 30 min. After further
washing of the sections there was a final incubation with a
complex of horse radish peroxidase and rabbit anti-horse
radish peroxidase (PAP complex) (Dako Labs., Bucks, UK)
at a dilution of 1:100 for 30min. All antibody incubations
were performed at room temperature in a humidified
chamber. Sections were again washed and the reaction prod-
uct that followed addition of hydrogen peroxide was
visualised by incubation with 0.02% 3-amino-9-
ethylcarbazole in 0.1 M acetate buffer (pH 5.2) for 20min.
This gives a red brown precipitate. Sections were finally
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washed and counterstained with Mayers Haemalun before
mouting in hydromount (Mensura Technology Ltd, Lancs,
UK). In addition, negative control slides were prepared using
a blocking peptide to exclude any non-specific binding.
Evaluation
Slides were evaluated by light microscopy; if at least one
focus of positively stained malignant cells was observed the
section was considered positive. Staining intensity was eval-
uated on a scale from 1 to 4 based on the proportion of
malignant cells in the section stained, grade 1 = up to 25%,
grade 2 = 25-50%, grade 3 = 50-75% and grade 4 = 75-
100%. Slides were initially read by one observer (J.W.) and
interobserver variation was determined after further assess-
ment by two independent pathologists. Two sections were cut
and stained separately from each slide and in doubtful or
borderline cases further sections were cut and stained in the
same way. There was full agreement in 95% of slides in both
assessment of staining and its grade, and an intratumour
variation rate of 6%.
Statistical methods
Survival analyses were performed to relate survival time to
c-erbB-2 staining (positive or negative), lymph node status
(positive or negative), oestrogen receptor status (positive or
negative) and tumour size (TI, T2 or T3). The close of the
study was taken as 1st January 1990, and patients known to
be alive at this date, or who had died earlier from causes
unrelated to cancer, were treated as censored observations.
Univariate analyses were performed using Kaplan-Meier
estimates and log-rank tests. Multivariate analysis was per-
formed with the Cox proportional hazards regression model,
using both forward and backward stepwise selection of vari-
ables. Tests for interactions were performed within the model
containing the main effects of all four prognostic variables.
Results
Histological sections of 465 tumours were incubated with
anti c-erbB-2; 361 (78%) failed to demonstrate any staining
whilst the remaining 104 (22%) stained positively. Staining
was confined primarily to the cell membrane of malignant
cells although, occasionally, some intracellular cytoplasmic
staining was seen. In one instance some faint staining was
seen in a focus of benign fibrocystic disease, but this was
surrounded by elements of intraductal carcinoma. No posi-
tive staining was seen in any of the benign breast biopsies
stained. Incubation of adjacent serial sections of the posi-
tively staining tumours with anti serum pre-incubated with
c-erbB-2 related peptide inhibited completely any staining.
The presence of c-erbB-2 was cross-tabulated with other
tumour variables (Table I). These included tumour size,
nodal status, and oestrogen receptor status. Although there
was a trend for the presence of c-erbB-2 staining to be
associated with larger tumours this failed to achieve statis-
tical significance (P = 0.054). No other associations of signifi-
cance were noted.
Univariate analysis ofoverall survival
c-erbB-2 The overall survival of the 104 patients whose
tumours expressed the c-erbB-2 protein was significantly
worse than in those whose tumours failed to express it (Log
rank x2 = 4.90, 1 d.f., P = 0.03). The improved survival of
patients with negatively stained tumours was maintained
throughout the period of follow up (Figure 1).
Lymph node status As expected, lymph node status was
found to be a powerful predictor of survival, with node
positive patients having a poor prognosis (Log rank X2=
44.96, 1 d.f., P<0.0001). Within each of the two groups
defined by nodal status, c-erbB-2 expression was consistently
Table I Tumour variables
Node negative 296 (64%)
Node positive 166 (36%)
Tumour size T, 43 (10%)
T2 310 (70%)
T3 80 (20%)
ER positive 257 (57%)
ER negative 194 (43%)
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Figure 1 Relationship of c-erbB-2 to overall survival.
associated with poor prognosis although this was only statis-
tically significant for node negative patients (log rank x2 =
4.45, P<0.03) (Figure 2).
Oestrogen receptor status There was no consistent associa-
tion between oestrogen receptor status and survival (log rank
x2 = 2.90, 1 d.f., P = 0.09). Stratifying the patients further by
c-erbB-2 status also gave no suggestion of a consistent
association between oestrogen receptor status and survival,
although there was a non-significant trend towards a poorer
prognosis was seen in oestrogen receptor positive patients
expressing the c-erbB-2 protein (Figure 3).
Tumour size
Tumour size was also found to be a powerful prognostic
factor (log rank x2 = 19.10, 2 d.f., P = 0.0001).
Multivariate analysis ofoverall survival
Nodal status and tumour size were clearly powerful indepen-
dent prognostic factors, and, controlling for these, c-erbB-2
was also significantly related to survival. Table II summarises
the result of the Cox regression with these three variables.
Controlling for nodal status, tumour size and c-erbB-2 status,
there was no significant association between oestrogen recep-
tor status and survival (X2 = 0.08, 1 d.f., P = 0.78).
None of the possible pairwise or higher order interaction
terms were statistically significant, implying that the effect of
c-erbB-2 expression on survival is similar over the various
prognostic groups defined by combinations of nodal status
and tumour size.
Relationship between grade ofstaining and survival
Degree of staining was evaluated on a scale of I to 4 based
on the percentage of cells stained. Eighteen percent were
grade 1, 27% grade 2, 31% grade 3 and 23% grade 4. When
the duration of survival of these four groups was compared
no significant difference was observed.
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Table II Regression coefficients for the Cc
model for cancer-related d
Standard Cl
Variable Coefficient error (SE)
Nodal status 0.793 0.147
Tumour size
T, -0.822 0.322
T2 --0.505 0.166
T3 0.0 -
c-erbB-2* 0.327 0.166
Coded; 0 = negative, I = positive.
Discussion
The purpose of this investigation was tc
expression and clinical significant of tl
erbB-2 in patients presenting with prima
found that the c-erbB-2 receptor was
patients. Although this level of express
noted in other series it is not as high
some (Slamon et al., 1987, 1989). It ha
archival paraffin-embedded material
expression because antigens may be
(Slamon et al., 1989). In order to eva
separate study (results not reported) i
freshly collected tissue fixed in methac;
after fixation in exactly the same way .
brbB-2(+)/node(-) A similar level ofexpression was seen in this group to that in
,rbB-2(-)/node(-) the archival group. Moreover, the same results were obtained
rbB-2(-)/node(+) with an entirely separate monoclonal antibody to c-erbB-2.
Similarly, although multiple serial sections were not stained
.-.--.-.--------B routinely, at least two sections from the same histological
A blocks were stained giving almost identical results, and the
consistency of findings in those cases in which staining of
~~~~~-D multiple sections was undertaken was such that heterogeneity
C ofexpression of c-erbB-2 is not affecting the reported results.
The expression of c-erbB-2 in this study is not associated
with other tumour variables, except perhaps a weak trend
towards an association with larger tumours. The differences
8 10 12 between those studies in which statistically significant associ-
ation has been noted between the expression of c-erbB-2 and
36 23 4 such variables as both nodal involvement (Slamon et al.,
151 100 31 1987; Zhou et al., 1987) and histological grade (Berger et al.,
16 8 1 51 35 10 1988) may reflect differences in the characteristics of the
urvival in nodal sub- populations of tumours considered. In this study 70% of the
tumours were T2 tumours and 60% were from patients
without involved lymph nodes. Other studies in which associ-
ations have been observed with both tumour size and nodal
status have consisted of a much higher proportion ofpatients
with axillary metastases or larger tumours (Slamon et al.,
:-erbB-2(+)/ER(+) 1989). With such a relatively small percentage of tumours
:-erbB-2(+)/ER(-) expressing the c-erbB-2 receptor, small changes in the
:-erbB-2(-)/ER(+) numbers expressing the receptor result in marked changes in
:-erbB-2(-)/ER(-) statistical significance, for even moderately sized groups. This
______-------- C underlines the importance of studying large numbers of
'___________D B patients when evaluating the prognostic usefulness of the
A c-erbB-2 receptor.
Overall survival for patients with tumours expressing the
c-erbB-2 receptor was significantly worse than in those with
tumours not expressing it. This poor prognostic effect was
observed throughout the period of follow-up, and these find-
ings are similar to those observed in other studies (Slamon et
8 10 12 al., 1989; Wright et al., 1989a; Lovekin et al., 1989).
25 13 1 Of particular clinical interest is the observation that the
27 18 4 presence of c-erbB-2 in tumours may identify a sub-group of
121 85 19 node negative patients with a poorer prognosis, and this has 78 48 21 ngtv ihponss
been observed in other studies (Wright et al., 1989a); Richner
val in oestrogen recep- et al., 1990). The ability to distinguish patients within this
ostensibly low risk group who are subject to early relapse of
their disease is of potential practical value for the selection of
patients for entry into adjuvant chemotherapy trials. The
expression of the c-erbB-2 receptor in primary tumour has
)x proportional hazards been shown to be associated with poor survival in patients
leath when treated with tamoxifen at time of recurrence (Wright et
oefficient al., 1989b). The presence of c-erbB-2 may therefore be of use
SE P-value in selecting patients who may not be suitable for treatment
5.38 <0.0001 with tamoxifen alone without the use of surgery.
Although this study indicates that the presence of c-erbB-2
-2.55 receptor protein appears to affect prognosis in primary breast
-3.04 0.003 cancer, several important questions remain to be answered
- both in relation to its clinical utility and to its biological role
1.97 0.05 in breast cancer. In pilot studies on ductal carcinoma in situ
(DCIS) the percentage of patients with tumours expressing
the c-erbB-2 receptor is apparently higher (42%) than in
established invasive breast cancer and is associated partic-
ularly with those of the commedo pattern (van der Vijver et
al., 1988; Barnes et al., 1988). Because this particular histo-
logical type is also associated with more aggressive tumour
behaviour it has been suggested that c-erbB-2 may be invol-
establish the level of ved in driving proliferation in the early stages of the disease
he proto-oncogene c- (van de Vijver et al., 1988). However, all in situ lesions may
ary breast cancer. We not progress to invasive lesions or alternatively expression of
expressed in 22% of this gene is retained in only that proportion of tumours
;ion is similar to that which grow at faster rates. Thus the presence of this receptor
ias that reported by in small and in situ carcinomas may be of even more value as
,s been suggested that a prognostic indicator than in established breast carcinomas.
may under-represent The mechanism by which the c-erbB-2 oncogene induces
lost during storage malignant change are not fully understood. However, the
luate this problem a mutated form of the neu gene that induces malignant change
was undertaken with in transgenic mice is not observed in human breast carcin-
arn and stained soon omas (Lemoine et al., 1990) and it probably requires activa-
as the archival tissue. tion by an external ligand for expression of the neoplastic
v! Il
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phenotype in breast cancer. This ligand may be a novel
growth factor which, after binding, modifies the response of
cells expressing the receptor to such factors as tumour necro-
sis factor (Hudziack et al., 1989) or part of a cell-cell
signalling apparatus (Gusterson et al., 1988; Quirke et al.,
1989).
Our results indicate that the proto-oncogene c-erbB-2 is
associated with a poor prognosis in breast cancer. It remains
to be determined what clinical significance it has in early and
in situ breast cancers and what role it plays in the develop-
ment of the disease.
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